Clinical trials: sponsored by Almirall, S.A.
Actinic Keratosis
Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis
The aim of this study is to determine the efficacy, safety and tolerability of either a once or twice daily topical application of LAS41007 compared to a twice daily application of LAS106521 in the treatment of actinic keratosis.
- Trial name
- NCT00991861
- Testing
- LAS41007 o.d., LAS41007 b.i.d., LAS106521
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Almirall, S.A.
Psoriasis
Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis
The aim of the study is to intra-individually compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT)
- Trial name
- NCT01119339
- Testing
- LAS 41004, LAS 41004 dosage 6, Reference
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Almirall, S.A.
Psoriasis
Clinical Trial to Investigate Efficacy of LAS41004 in Psoriasis
The aim of the study is to intra-individually compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT)
- Trial name
- NCT01283698
- Testing
- Experimental: LAS 41004 dosage 1, Experimental: LAS 41004 dosage 2, Experimental: LAS 41004 dosage 3
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Almirall, S.A.
Chronic Obstructive Pulmonary Disease (COPD)
Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD
Preference study: Genuair® (Pressair™) vs Breezhaler® (Neohaler™) inhalers in patients with COPD
- Trial name
- NCT01915784
- Testing
- Genuair®, Breezhaler®
- Where
- 6 sites in Germany, Spain and 1 more
- Volunteers
- 128 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
LAS41005 in Hyperkeratotic Actinic Keratosis
The aim of this study is to evaluate the efficacy and safety of LAS 41005 compared to cryotherapy in subjects with moderate to severe hyperkeratotic actinic keratosis (punch biopsies).
- Trial name
- NCT01358851
- Testing
- Cryotherapy, LAS41005
- Where
- 4 sites in Germany
- Volunteers
- 67 people
- Sponsor
- Almirall, S.A.
Psoriasis
Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test
Clinical investigation of anti-psoriatic efficacy and atrophy
- Trial name
- NCT02111499
- Testing
- LAS41004-IMP1, LAS41004 IMP2, LAS41004 IMP3
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Almirall, S.A.
Asthma
A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid
The purpose of this study is to assess the the ability of a single dose of LAS40468 administered via Genuair® and a single dose of salmeterol/fluticasone propionate (Seretide®) administered via Accuhaler to produce…
- Trial name
- NCT02094274
- Testing
- LAS40468, Salmeterol/fluticasone propionate
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Almirall, S.A.
Multiple Sclerosis
Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity
Aim of this randomized, double-blind, placebo-controlled, cross-over study is to investigate cannabinoid-induced changes in neurophysiological parameters in a group of 40 patients with secondary or primary progressive Multiple…
- Trial name
- NS-MSS (NCT01538225)
- Testing
- Sativex®
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis
The aim of this study is to determine the efficacy, safety and tolerability of LAS41007 compared to a marketed reference product as well as to vehicle (topical application, twice daily, indication mild to moderate AK).
- Trial name
- NCT01265602
- Testing
- LAS41007, LASW1510, vehicle of LAS41007
- Where
- Germany
- Volunteers
- 889 people
- Sponsor
- Almirall, S.A.
Tinea Pedis
Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis
The aim of this study is to determine the efficacy and safety of a topical application of the combinational cream LAS41003 compared to application of its mono-substances after once daily treatment in patients with inflammatory…
- Trial name
- NCT01096472
- Testing
- LAS41003, LAS189961, LAS189962
- Where
- 2 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Almirall, S.A.
Candidiasis
Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections
The aim of this study is to determine the efficacy and safety of once daily topical application of the combinational cream LAS41003 compared to the corresponding mono-substances in the treatment of candida infections in…
- Trial name
- NCT01102387
- Testing
- LAS41003, LAS189962, LAS189961
- Where
- 6 sites in Germany
- Volunteers
- 137 people
- Sponsor
- Almirall, S.A.
Psoriasis
Efficacy and Tolerability of LAS41004 Formulations in a Non-occlusive Psoriasis Plaque Test
The aim of the exploratory study is to compare dose related effects of LAS41004 formulations in a non-occlusive PPT.
- Trial name
- PPT4 (NCT01462643)
- Testing
- LAS41004
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Almirall, S.A.
Atopic Eczema
Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema
The aim of the study is an intra-individual comparison of skin conditions in addition to a patient based assessment of product appearance in the topical treatment of atopic eczema.
- Trial name
- NCT01119313
- Testing
- LAS 41002, Active
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Almirall, S.A.
Eczema
Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema
The aim of the study is to determine the efficacy and safety of topical application of LAS41003 in comparison to LAS189962 and LAS189961 in the treatment of superinfected eczema.
- Trial name
- NCT01020994
- Testing
- LAS41003, LAS189962, LAS189961
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Almirall, S.A.